A bitter battle over the 'orphan drug' program leaves patients' pocketbooks at risk

Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.

Related Keywords

Minnesota ,United States ,Kentaji Brown Jackson ,Rachel Sher ,Mary Carmichael ,David Schull ,George Obrien ,Richard Burr ,Mayer Brown ,Bernie Sanders ,Us Supreme Court ,Catalyst Pharmaceuticals Inc ,Us Circuit Court ,National Organization For Rare Disorders ,Commerce Committee ,House Energy ,Novartis ,Lore Wilkinson ,April Grant ,Catalyst Pharmaceutical Firdapse ,Jacobus Pharmaceutical ,Catalyst Pharmaceuticals ,Orphan Drug Act ,Orphan Drug ,National Organization ,Rare Disorders ,Capitol Hill ,